Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02268214 · ClinicalTrials.gov registry record · Phase 3
Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 833
- Enrollment target
NCT02268214 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 833 participants.
The verdict
NCT02268214, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 833 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.
Interventions
- DRUG Dapagliflozin
- DRUG Placebo for dapagliflozin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 833 participants |
| Start Date | 2014-11-11 |
| Est. Completion | 2017-08-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02268214
The ClinicalTrials.gov registry entry for NCT02268214 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 833 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dapagliflozin is the first listed.
NCT02268214 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02268214 about?
NCT02268214 is a clinical study titled "Dapagliflozin Evaluation in Patients With Inadequately Controlled Type 1 Diabetes". The purpose of this study is to determine if adding dapagliflozin to insulin is a safe and effective therapy to improve glycemic control in patients with type 1 diabetes.
What is the current status of trial NCT02268214?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 833 participants. The study started on 2014-11-11. Estimated completion is 2017-08-25.
What interventions are being tested in trial NCT02268214?
The interventions under investigation include: Dapagliflozin (DRUG), Placebo for dapagliflozin (DRUG).
Who is sponsoring clinical trial NCT02268214?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.